drugset / Trial / NCT01352221

Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)

NCT01352221

Phase 3 Completed 128 enrolled Shield Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether ST10-021, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in subjects with non-active Crohn's Disease (CD).

Timeline

Start
2011-08
Primary completion
2013-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric maltol Small molecule 30 mg Oral